FDA’s Quest For More MDR Exemption Requests Leaves Device Industry Jittery
This article was originally published in The Silver Sheet
Executive Summary
A draft Medical Device Reporting guidance from FDA has concerned industry experts who say the document would require manufacturers to spend an onerous amount of time submitting requests for exemption to the agency’s MDR regulation. The draft removes a longstanding so-called “two-year rule” for reporting, calls for firms and contract manufacturers to jointly seek exemptions, and asks companies to file an exemption request after selling a 510(k). Close observers suggest the agency is proposing the modifications to make it clearer to agency investigators and companies when MDRs are in fact required. FDA also likely wants to maximize the useful post-market information it receives rather than cutting off MDR reports superficially, outside attorneys explain. But some experts argue the increased emphasis on exemptions would add more burden to companies and FDA with little benefit.
You may also be interested in...
MDR Guidance: Most User Errors Should Be Tracked, Not Reported As Adverse Events, FDA Says
Device manufacturers should track and trend quality information that shows that a product was used incorrectly, and not necessarily file a Medical Device Report, US FDA guidance says. The document also includes a bevy of other advice, including MDR reporting requirements around contract manufacturing, exemptions and product problems discovered in literature.
Two-Year Medical Device Reporting Window Retained In New FDA Final MDR Guidance
The US agency has clarified its current thinking on Medical Device Reporting in a new final guidance that allows manufacturers to continue using a so-called “two-year rule” that lets them stop sending MDRs to the agency after 24 months. Overall, the guidance is a roadmap for how firms should structure MDR programs.
Year In Review: Complaint Handling, UDI, FDA Inspections, And More
The top quality-related topics manufacturers faced last year included a new FDA regulation to track and trace devices, innovative supply chain initiatives and an update to the agency’s Medical Device Reporting guidance, among others. Plus honorable mentions: product recalls, human factors and FDA compliance meetings.